Literature DB >> 21139098

Targeted epigenetic therapies: the next frontier?

Rabiya S Tuma.   

Abstract

Mesh:

Substances:

Year:  2010        PMID: 21139098     DOI: 10.1093/jnci/djq520

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

Review 1.  p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Authors:  Yogen Saunthararajah; Pierre Triozzi; Brian Rini; Arun Singh; Tomas Radivoyevitch; Mikkael Sekeres; Anjali Advani; Ramon Tiu; Frederic Reu; Matt Kalaycio; Ed Copelan; Eric Hsi; Alan Lichtin; Brian Bolwell
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

Review 2.  Epigenetic Regulation of Dendritic Cell Development and Function.

Authors:  Yuanyuan Tian; Lijun Meng; Yi Zhang
Journal:  Cancer J       Date:  2017 Sep/Oct       Impact factor: 3.360

3.  Reversible epigenetic histone modifications and Bdnf expression in neurons with aging and from a mouse model of Alzheimer's disease.

Authors:  Michael P Walker; Frank M LaFerla; Salvador S Oddo; Gregory J Brewer
Journal:  Age (Dordr)       Date:  2012-01-12

4.  Potential markers for detection and monitoring of ovarian cancer.

Authors:  Brandon J D Rein; Sajal Gupta; Rima Dada; Joelle Safi; Chad Michener; Ashok Agarwal
Journal:  J Oncol       Date:  2011-04-11       Impact factor: 4.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.